Get the Stockscreener App
0.63
0.16%
-0.001
Chromocell Therapeutics Corp stock is traded at $0.63, with a volume of 14,738.
It is down -0.16% in the last 24 hours and down -9.42% over the past month.
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
See More
Previous Close:
$0.631
Open:
$0.69
24h Volume:
14,738
Relative Volume:
0.13
Market Cap:
$3.75M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.35%
1M Performance:
-9.42%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.6255
$0.69
1-Week Range:
$0.6255
$0.69
52-Week Range:
$0.52
$1.11
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
Name
Chromocell Therapeutics Corp
Sector
Industry
Phone
(917) 644-6313
Address
685 US HIGHWAY ONE, NORTH BRUNSWICK
Compare CHRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CHRO | 0.63 | 3.75M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Chromocell Therapeutics Corp Stock (CHRO) Latest News
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com
Chromocell to Present at Upcoming Fall Investor Conferences - The Manila Times
Chromocell announces amendment to stock repurchase plan - MSN
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell boosts stock buyback plan to $750,000 - Investing.com India
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Chromocell boosts stock buyback plan to $750,000 By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Upward Trajectory: Chromocell Therapeutics Corp. (CHRO) Posts a Slidee, Closing at 0.84 - The Dwinnex
CHRO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Chubb (CB) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Stocks of Chemours Company (CC) are poised to climb above their peers - SETE News
Chubb Limited [CB] stock was sold by GREENBERG EVAN G at the price of US$8.78 million - Knox Daily
Recent 4.1% pullback isn't enough to hurt long-term Calumet (NASDAQ:CLMT) shareholders, they're still up 373% over 5 years - Yahoo Finance
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $18.00 - Defense World
Market Update: Calumet Inc. (CLMT) Sees Negative Movement, Closing at 18.00 - The Dwinnex
C.H. Robinson Worldwide Sees Unusually High Options Volume (NASDAQ:CHRW) - MarketBeat
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CG Oncology initiated with an Outperform at RBC Capital - TipRanks
Comparing BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) - Defense World
Chubb Stock Trading Near 52-Week High: What Should Investors Know? - Yahoo Finance
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Morningstar
Choreo LLC Purchases New Stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
CorMedix stock soars to 52-week high, hits $7.29 By Investing.com - Investing.com Australia
Investor’s Delight: Calumet Inc. (CLMT) Closes Weak at 18.24, Down -0.27 - The Dwinnex
Analyzing Calumet Inc. (CLMT) After Recent Trading Activity - Knox Daily
Another Delaware Publicly Traded Company Proposes A Nevada Move - The National Law Review
Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St
Chubb (CB) Rises Higher Than Market: Key Facts - Yahoo Finance
Chromocell therapeutics CEO buys $5,044 in company stock By Investing.com - Investing.com Canada
Chromocell therapeutics director buys $9.8k in stock - Investing.com
Chromocell therapeutics CEO buys $5,044 in company stock - Investing.com India
Chubb Ltd. stock rises Monday, outperforms market - MarketWatch
Life Sciences Virtual Investor Forum Agenda Announced for September 19th - GlobeNewswire
Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewswire
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $16.58 - Defense World
Chromocell Therapeutics CEO buys shares worth over $10,000 By Investing.com - Investing.com Australia
Market Recap Check: Calumet Inc. (CLMT)’s Positive Finish at 16.58, Up/Down 10.31 - The Dwinnex
Chromocell Therapeutics CEO buys shares worth over $10,000 - Investing.com
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024 - MSN
Chromocell announces $250,000 stock repurchase plan By Investing.com - Investing.com Australia
Chromocell Therapeutics announces stock repurchase plan up to $250,000 - TipRanks
Chromocell Therapeutics Co.’s Lock-Up Period Will End on August 14th (NYSE:CHRO) - Defense World
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Chromocell Therapeutics Corp Stock (CHRO) Financials Data
There is no financial data for Chromocell Therapeutics Corp (CHRO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Cap:
|
Volume (24h):